A Phase 3 interventional study of Suzetrigine in Pain, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 14 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-07-01.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing suzetrigine in Pain — 4 open to participants now, 4 under way, 2 of them phase 3. suzetrigine · Pain.
Among the 21 studies testing suzetrigine in Pain, this one has the largest enrollment, is one of 4 that started in 2023, is one of 3 in phase 3, and was the 5th registered.
10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.
Browse Pain studies →4 of the 21 studies testing suzetrigine in Pain are open now, in 1 country. Recruiting first, the newest first:
Hospital for Special Surgery, New York · Sites in United States
Ages 18–80 · Healthy volunteers
Hospital for Special Surgery, New York · Sites in United States
Ages 18–80 · Healthy volunteers
Stanford University · Sites in United States
Ages 18+
Jacob Lensing · Sites in United States
Ages 18–45
By country, each count listing its studies:
suzetrigine: first FDA approval 2025 (JOURNAVX). What it is approved for, and how studies give it, is on its page →
Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2022; this study’s year is marked. 4 started in 2023.
This study's enrollment of 258 is above the median of 66 across 8,505 interventional studies indexed under Pain.
Median enrollment 50 across the 21 interventional studies. Of the 17 that completed or were terminated, 1 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 21 have an industry lead sponsor. The 6 most frequent:
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.
26 studies in Pain by Vertex Pharmaceuticals Incorporated: none open now, none under way, none of them phase 3. Of 26 finished, 1 (4%) have results posted.
Among the 26 studies in Pain by Vertex Pharmaceuticals Incorporated, this one has the largest enrollment, is one of 5 that started in 2023, is the only one in phase 3, and was the 8th registered.
Vertex Pharmaceuticals Incorporated’s Pain studies by the year they started, since 2022.
2 of the studies testing suzetrigine in Pain that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07226700Phase 3Hospital for Special Surgery, New YorkSuzetrigine in Total Hip Arthroplasty | 2027-11-01 |
| NCT07821931Stanford UniversitySuzetrigine in Tonsillectomy for Opioid-sparing Pain Management | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 21 studies testing suzetrigine in Pain, from their registry updates:
Among Vertex Pharmaceuticals Incorporated’s 26 in Pain:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and effectiveness of VX-548 in treating acute pain.
Key Inclusion Criteria:
Key Exclusion Criteria:
Surgical participants:
Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received SUZ 100 milligram (mg) as first dose, followed by SUZ 50 mg every 12 hours (q12h) for 14 days or until pain resolves, whichever occurs first.
Drug: Suzetrigine
Tablets for oral administration.
Also known as: VX-548, SUZ
Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame: Day 1 up to Day 30
Percentage of Participants Reporting Good, Very Good, or Excellent on a Patient Global Assessment (PGA) Scale
The PGA is a single-item assessment of patient perceptions of the method of pain control with the study drug and is evaluated on a 5-point Likert scale as: (poor, fair, good, very good or excellent). Percentage of participants who reported good, very good or excellent on the PGA scale was reported.
Time frame: Day 14 or at Pain Resolution, whichever occurs first
| Milestone | Suzetrigine (SUZ) |
|---|---|
| Started | 258 |
| Safety set | 256 |
| Completed | 240 |
| Not completed | 18 |
| Withdrew: Withdrawal of consent (not due to ae) | 3 |
| Withdrew: Lost to follow-up | 13 |
| Withdrew: Enrolled but not dosed | 2 |
| Participants | Suzetrigine (SUZ) |
|---|---|
| Participants with TEAEs | 94 |
| Participants with SAEs | 2 |
The PGA is a single-item assessment of patient perceptions of the method of pain control with the study drug and is evaluated on a 5-point Likert scale as: (poor, fair, good, very good or excellent). Percentage of participants who reported good, very good or excellent on the PGA scale was reported.
| percentage of participants | Suzetrigine (SUZ) |
|---|---|
| Percentage of Participants Reporting Good, Very Good, or Excellent on a Patient Global Assessment (PGA) Scale | 83.2 |
Collected over Day 1 up to Day 30. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Suzetrigine (SUZ) | 0/256 (0%) | 2/256 (0.8%) | 18/256 (7%) |
| Event | Suzetrigine (SUZ) |
|---|---|
| CellulitisInfections and infestations | 1/256 |
| Suicidal ideationPsychiatric disorders | 1/256 |
| Event | Suzetrigine (SUZ) |
|---|---|
| HeadacheNervous system disorders | 18/256 |
Baseline data was analyzed based on the Full Analysis Set (FAS), defined as all participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Suzetrigine (SUZ) |
|---|---|
| Mean | 43.9 ± 14.1 |
| Sex: Female, Male(Participants) | Suzetrigine (SUZ) |
|---|---|
| Female | 173 |
| Male | 83 |
| Race/Ethnicity, Customized(Participants) | Suzetrigine (SUZ) |
|---|---|
| Hispanic or Latino | 108 |
| Not Hispanic or Latino | 148 |
| Race/Ethnicity, Customized(Participants) | Suzetrigine (SUZ) |
|---|---|
| White | 214 |
| Black or African American | 34 |
| Asian | 3 |
| American Indian or Alaska Native | 3 |
| Native Hawaiian or other Pacific Islander | 1 |
| Multiracial | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing
Ran from Jan 2023 to primary completion in Dec 2023, 11 months.
Results were first posted in Jul 2025, 1 year 6 months after primary completion. A results delay was requested in Dec 2024.
Of 105 industry-sponsored phase 3 interventional studies under Pain, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 23. This study's 11 months is below that.
Counting every sponsor, half of 216 studies reached it within 18 months; a quarter within 9 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Suzetrigine
Vertex Pharmaceuticals Incorporated →